Elixir Medical concludes first-in-man study for coronary scaffold system

Medical device developer Elixir Medical (Sunnyvale, CA) presented intravascular ultrasound (IVUS), optical coherence tomography (OCT), and angiographic data from its 15-patient, first-in-man clinical trial of its DESolve bioresorbable coronary scaffold system. The system is made from the company's poly-L Lactide (PLLA)-based polymer to provide strength and support to the artery while delivering an anti-proliferative drug, and is designed to resorb in the body within 1–2 years.

At six months, the system demonstrated late lumen loss of 0.19 ± 0.19 mm, no reblockage of the artery (0.0% binary restenosis), no late malapposition (0.0%), low acute recoil (6.4% ± 4.3), no cases of blood clots (0.0% stent thrombosis), and a single major adverse cardiac event (MACE) due to a stenosis in the segment 5 mm proximal to the scaffold, which itself was widely patent. Imaging results also demonstrated low neointimal volume obstruction of 7.1% and no late recoil or scaffold shrinkage. OCT, which provides high-resolution intravascular imaging, confirmed the results and showed that over 98% of the scaffold struts were covered with a thin, uniform neointimal layer (0.12 mm) at 6 months. The 15 patients were enrolled in Europe and New Zealand, and will continue to be followed up at subsequent yearly intervals for 5 years.

"Bioresorbable scaffolds that restore the coronary vessel to its normal form and function without leaving a permanent implant in the body have long been considered the ultimate frontier in interventional cardiology," says Stefan Verheye, MD., Ph.D., ZNA Middleheim Hospital (Antwerp, Belgium), and principal investigator of the DESolve I Study, who presented the results. The system could also eliminate the need for long-term dual anti-platelet therapy, he notes.

The company has initiated a pivotal trial, DESolve Nx, which is currently enrolling 120 patients across Europe, New Zealand, and Brazil, and will evaluate the safety and efficacy of the system. The primary angiographic endpoint of the trial will be in-stent late lumen loss at 6 months for all patients as assessed by quantitative coronary angiography (QCA).

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Follow sister publication Laser Focus World on your iPhone or Android

Subscribe now to BioOptics World magazine; it's free!

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

OCT imaging improves percutaneous coronary intervention, study finds

OCT can visualize coronary arteries in patients undergoing percutaneous coronary intervention, leading to improved outcomes.

Eye test that pairs two in vivo imaging methods may detect Parkinson's earlier

A low-cost, noninvasive eye test pairs two in vivo imaging methods to help detect Parkinson's before clinical symptoms appear.

Lightweight handheld probe for OCT provides insight into children's retinas

A handheld device is capable of capturing OCT images of a retina with cellular resolution in infants and toddlers.

Optical brain imaging noninvasively measures small perfusion changes caused by visual stimulation

An optical brain imaging system can track very small, focal changes in cortical perfusion resulting from visual stimulation.

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS